Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Muparfostat
- Development stage
- Phase 2
- Lead developer
- Medigen Biotechnology
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Muparfostat (PI-88) is a heparan sulfate mimetic and a complex mixture of sulfated oligosaccharides. It functions primarily as a heparanase inhibitor, which allows it to block angiogenesis, metastasis, and tumor growth. The drug has been investigated for its anti-cancer properties, progressing to Phase III clinical trials, though it was ultimately not approved for this indication. Additionally, Muparfostat has been shown to bind to lipoprotein lipase, which can lead to hyperlipidemia and aggravate hepatic steatosis in obese individuals. It also exhibits antiviral activity against viruses such as herpes simplex virus (HSV) and vaccinia virus (VACV), and has been studied for its potential in hypoxia-induced retinal neovascularization.
- Other names
- PI-88PI88PI 88
02
Targets
VEGFA (Vascular endothelial growth factor A)FGF1 (Fibroblast growth factor 1)HPSE (Heparanase)FGF2LPL (Lipoprotein lipase)
Beyond the preview
Go deeper on Muparfostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Muparfostat.